Evaluating the Safety and Effectiveness of Spirulina-Derived Anti-Fungal Treatment

Research on Natural Anti-Fungal Treatment Derived from Spirulina

Background on Fungal Infections

Superficial fungal infections, known as dermatophytosis, affect approximately 25% of the global population. While topical anti-fungal creams can be effective, untreated or improperly treated infections may become chronic, leading to complications such as bacterial superinfections. Chronic cases often necessitate the use of oral antifungals, which can pose risks including liver toxicity. Certain fungal infections, such as onychomycosis (nail infections) and tinea (skin infections), may resist conventional treatments, making topical solutions often ineffective.

Introduction of Calmagen®

Calmagen®, a novel anti-fungal cream containing a bioactive extract from spirulina, has shown promise in treating fungal infections. The active ingredient, AMYCOT®, comprises a unique blend of molecules that work synergistically against fungal pathogens. Although Calmagen® has undergone preclinical and non-randomized human trials, further randomized clinical trials are essential to evaluate its safety and efficacy.

Study Design and Methodology

To address the need for more rigorous trials, researchers from India conducted a randomized, placebo-controlled, double-blinded, parallel group study at a single center in Bangalore. This study aimed to evaluate the safety and efficacy of Calmagen® for treating severe to very severe onychomycosis and tinea. The findings were published in BMC Complementary and Alternative Medicine.

Participant Selection and Treatment Protocol

The study involved men and women aged eighteen or older who consented to participate. All participants underwent clinical assessments, and positive fungal cultures and potassium hydroxide (KOH) smears confirmed the presence of live fungal spores. A total of 28 participants met the inclusion criteria, with 18 suffering from tinea and 10 from onychomycosis. Participants were randomly assigned to treatment or control groups, applying either Calmagen® or a placebo. Those with tinea used the cream twice daily for four weeks, while onychomycosis patients applied it to the nail bed and cuticle twice daily for twelve weeks, followed by once-daily application for another twelve weeks.

Results and Outcomes

At the conclusion of the study, researchers evaluated KOH smears, fungal cultures, and live spore counts to assess the efficacy of the treatment. Significant differences were noted between the treatment and control groups. Thirteen of fourteen participants in the treatment group had negative KOH smears after treatment, whereas all control participants retained positive smears. Additionally, all treatment group members exhibited negative fungal cultures and live spore counts, compared to only six control participants.

Secondary outcomes showed that both tinea and onychomycosis participants experienced considerable improvements in lesion size and severity, as confirmed by photographic evidence. Importantly, no adverse events were reported during the study.

Future Directions

While these findings are promising, larger clinical trials are necessary to validate the results. The small sample size limited the researchers’ ability to stratify participants by infection type, severity, or treatment form. The potential for fungal infections to recur post-treatment also requires further investigation. As fungal infections are common and often resistant to standard treatments, exploring alternatives like Calmagen® is essential, particularly given the side effects associated with current treatments.

Conclusion

The results indicate that Calmagen® may represent a safe and effective option for treating severe fungal infections, including onychomycosis and tinea, leveraging the natural properties of spirulina.

Written by Suzanne M. Robertson, Ph.D.

Parekh, Manoj, et al. “A pilot single centre, double blind, placebo controlled, randomized, parallel study of Calmagen® dermaceutical cream and lotion for the topical treatment of tinea and onychomycosis.” BMC Complementary and Alternative Medicine 17.1 (2017): 464.